Palo Alto Investors LP Sage Therapeutics, Inc. Transaction History

Palo Alto Investors LP

$727 Million
Q3 2024

A detailed history of Palo Alto Investors LP transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Palo Alto Investors LP holds 1,010,833 shares of SAGE stock, worth $4.96 Million. This represents 1.0% of its overall portfolio holdings.

Number of Shares

1,010,833

Previous 1,010,833 -0.0%

Holding current value

$4.96 Million

Previous $11 Million 33.61%

% of portfolio

1.0%

Previous 1.39%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$10.58 - $17.9 $53,503 - $90,520	5,057 Added 0.5%	1,010,833 $11 Million
Q1 2024 May 15, 2024	BUY	$18.62 - $26.95 $265,353 - $384,064	14,251 Added 1.44%	1,005,776 $18.8 Million
Q4 2023 Feb 14, 2024	SELL	$17.1 - $22.26 $243,692 - $317,227	-14,251 Reduced 1.42%	991,525 $21.5 Million
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $2.45 Million - $7.16 Million	146,259 Added 17.02%	1,005,776 $20.7 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $46.57 $111,810 - $139,710	3,000 Added 0.35%	859,517 $36.1 Million
Q4 2022 Feb 14, 2023	BUY	$32.2 - $43.61 $164,477 - $222,759	5,108 Added 0.6%	856,517 $32.7 Million
Q2 2022 Aug 15, 2022	SELL	$27.52 - $37.99 $8,531 - $11,776	-310 Reduced 0.04%	851,409 $27.5 Million
Q1 2022 May 16, 2022	BUY	$30.71 - $45.71 $2.15 Million - $3.2 Million	69,989 Added 8.95%	851,719 $28.2 Million
Q4 2021 Feb 14, 2022	BUY	$37.06 - $47.11 $6.07 Million - $7.72 Million	163,800 Added 26.51%	781,730 $33.3 Million
Q3 2021 Nov 15, 2021	BUY	$40.26 - $57.37 $701,731 - $999,959	17,430 Added 2.9%	617,930 $27.4 Million
Q1 2021 May 17, 2021	BUY	$70.65 - $96.76 $727,695 - $996,628	10,300 Added 1.75%	600,500 $44.9 Million
Q3 2020 Nov 16, 2020	BUY	$41.13 - $62.45 $616,950 - $936,750	15,000 Added 2.61%	590,200 $36.1 Million
Q2 2020 Aug 14, 2020	SELL	$25.95 - $43.15 $297,750 - $495,103	-11,474 Reduced 1.96%	575,200 $23.9 Million
Q1 2020 May 15, 2020	SELL	$26.15 - $77.24 $1.75 Million - $5.17 Million	-66,920 Reduced 10.24%	586,674 $16.8 Million
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $1.64 Million - $4.23 Million	-27,300 Reduced 4.01%	653,594 $47.2 Million
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $16 Million - $21.7 Million	-114,137 Reduced 14.36%	680,894 $95.5 Million
Q2 2019 Aug 14, 2019	SELL	$157.85 - $183.09 $9.89 Million - $11.5 Million	-62,650 Reduced 7.3%	795,031 $146 Million
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $598,868 - $1.1 Million	6,704 Added 0.79%	857,681 $136 Million
Q4 2018 Feb 14, 2019	BUY	$81.94 - $139.71 $868,973 - $1.48 Million	10,605 Added 1.26%	850,977 $81.5 Million
Q3 2018 Nov 14, 2018	BUY	$138.11 - $169.04 $1.08 Million - $1.32 Million	7,836 Added 0.94%	840,372 $119 Million
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $1.99 Million - $2.5 Million	14,205 Added 1.74%	832,536 $130 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $1.14 Million - $1.45 Million	7,525 Added 0.93%	818,331 $132 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $1.43 Million - $3.94 Million	23,555 Added 2.99%	810,806 $134 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $48.3 Million - $69.7 Million	787,251	787,251 $49 Million

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $292M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Palo Alto Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Palo Alto Investors LP with notifications on news.

Account

Palo Alto Investors LP Sage Therapeutics, Inc. Transaction History